Close
A ‘wee molecule’: the tiny urinary biomarker neopterin and its role in MND progression

A ‘wee molecule’: the tiny urinary biomarker neopterin and its role in MND progression

Reading Time: 6 minutes My name is Stephanie Shepheard, and I am a Research Associate in the Motor Neuron Disease & Neurotrophic Research Laboratory (MND&NR Lab), Flinders Health & Medicine Research Institute in the College of Medicine & Public Health at Flinders University, South Australia. I measure biological changes, or biomarkers, that may tell us something useful about motor…

Identifying potential new diagnostic biomarkers in the blood

Reading Time: 6 minutes Guest researcher blog post about the recently published paper on the identification of potential new biomarkers in the blood, in the journal Brain Communications. Written by lead author, Dr Greig Joilin, Postdoctoral Research Fellow at the University of Sussex: Diagnosis of MND is currently a time-consuming process of elimination, causing patients and families prolonged stress…

Kennedy’s Disease vs ALS: How muscle patterns can aid diagnosis and perform as a novel biomarker

Reading Time: 3 minutes Researchers from University College London led by Dr Pietro Fratta and Dr John Thornton found that muscle imaging can help distinguish Amyotrophic Lateral Sclerosis (ALS) from Kennedy’s Disease based on the way specific muscle groups deteriorate in each condition. The method can also help assess the severity of the disease. ALS is a rapidly progressing…

Kennedy’s Disease: focus on muscle damage reveals key biomarker

Kennedy’s Disease: focus on muscle damage reveals key biomarker

Reading Time: 5 minutes Findings from the largest biomarker study of people with Kennedy’s Disease, published in the journal Neurology, found a predictive biomarker to help in differential diagnosis and tracking clinical progression. Led by Dr Pietro Fratta from University College London, the research team highlighted the importance of markers of muscle mass rather than neuronal damage in Kennedy’s…

Why we need biomarkers

Reading Time: 3 minutes Yesterday’s announcement by the biotechnology company Trophos SA of the lack of effectiveness of their compound olesoxime adds to the long list of drugs that have failed to live up to their early promise in the lab. It’s a story that’s common across the world of neurodegenerative disease, including common conditions such as Parkinson’s disease…

Workshop on closer European working

Reading Time: 2 minutes Last weekend 19 neurologists and researchers gathered in a hotel seminar room in The Netherlands to talk about building closer links across Europe. Prof Leonard van den Berg, the current chair of the European ALS Consortium organised the workshop to work out how we can collaborate more effectively across Europe. Prof van den Berg is…